Interpreting coagulation assays

Blood Coagulation and Fibrinolysis

Volumn 21, Issue SUPPL. 1, 2010, Pages

  Green, David ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Bethesda assay; coagulation factors; fibrinogen; partial thromboplastin time; prothrombin time

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8 INHIBITOR; D DIMER; FIBRINOGEN; HEPARIN; LUPUS ANTICOAGULANT; WARFARIN;

BETHESDA ASSAY; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TEST; BLOOD SAMPLING; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG MONITORING; HEMOPHILIA; HUMAN; LIVER DISEASE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; RECURRENT DISEASE; REVIEW; THROMBOSIS;

BLOOD COAGULATION TESTS; DIAGNOSTIC TECHNIQUES AND PROCEDURES; DRUG MONITORING; HUMANS;

EID: 77957564580     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mbc.0000388935.77612.d0     Document Type: Review

References (23)

1. Kitchens CS. Chapter 37: Surgery and Hemostasis. In: Kitchens CS, Alving BM, Kessler CM, editors. Consultative Hemostasis and Thrombosis, 2nd Edition Philadelphia: Saunders; 2007. pp. 619-621.
2. Laine C, Williams SV, Wilson JF. Preoperative evaluation. Ann Intern Med 2009;151: ITC1-14.
3. Sirridge M, Shannon R (1983). Modified Clauss method: in laboratory evaluation of hemostasis and thrombosis. 3rd ed. Philadelphia: Lea & Febiger. pp. 164-165.
4. Adam SS, Key NS, Greenberg CS. D-dimer antigen: current concepts and future prospects. Blood 2009;113:2878-2887.
5. Bruinstroop E, Klok FA, Van de Ree MA, Oosterwijk FL, Huisman MV. Elevated d-dimer levels predict recurrence in patients with idiopathic venous thromboembolism: a meta-analysis. J Thromb Haemost 2009;7:611-618.
6. Goodnight SH, Hathaway WE. Disorders of Hemostasis and Thrombosis, 2nd Edition New York: McGraw-Hill; 2001; p. 45.
7. Lissalde-Lavigne G, Combescure C, Dorangeon E, Lefrant J-Y, Gris J-C. Simple coagulation tests improve earlymortality prediction for patients in intensive care units who have proven or suspected septic shock. J Thromb Haemost 2007;5:1081-1083.
8. Boggio LN, Green D. Acquired hemophilia. Rev Clin Exp Hematol 2001;5:389-404.
9. Mannucci PM, Tuddenham EGD. The hemophilias-from royal genes to gene therapy. N Engl J Med 2001;344:1773-1779.
10. Bolton-Maggs PHB (1996). Factor XI deficiency inhaemophilia. In: CA Lee, editor. Baillierés clinical haematology. pp. 355-368.
11. Ewenstein BM. Chapter 6: Nonhemophilic inhibitors of coagulation. In: Kitchens CS, Alving BM, Kessler CM, editors. Consultative Hemostasis and Thrombosis, 2nd Edition Philadelphia: Saunders; 2007. pp. 81-83.
12. Rodgers SE, Duncan EM, Barbulescu DM, Quinn DM, Lloyd JV. In vivo kinetics of factor VIII activity in patients with mild haemophilia A and a discrepancy between one-stage and two-stage factor VIII assay results. Br J Haematol 2007;136:138-145.
13. Hellstern P, Kiehl R, Miyashita C, Schwerdt H, von Blohn G, Kohler M, et al. Factor VIII: C (FVIII:C) recovery and half-life after infusion of steam-treated high purity factor VIII concentrate in severe hemophilia A-comparison of one-stage assay, two-stage assay and a chromogenic substrate assay. Thromb Haemost 1986;56:353-359.
14. Rock G, Palmer DS. Disparity between one-and two-stage factor VIII assays in measuring VIIIC in heparinized plasma. Thromb Haemost 1985;54:780-783.
15. Kasper C, Aledort L, Counts R. A more uniform measurement of factor VIII inhibitors. Thrombosis Diath Haemorrh 1975;34:869-872.
16. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995;73:247-251.
17. Green D. Spontaneous inhibitors of factor VIII. Br J Haemotol 1968;15:57-75.
18. Kempton CL, White GC. How we treat a hemophilia A patient with a factor VIIII inhibitor. Blood 2009;113:11-17.
19. Franchini M, Lippi G. Acquired factor VIII inhibitors. Blood 2008;112:250-255.
20. Green D. The management of acquired haemophilia. Haemophilia 2006;12(Suppl 5):32-36.
21. Shima M, Matsumoto T, Fukuda K, Kubota Y, Tanaka I, Nishiya K, et al. The utility of activated partial thromboplastin time (aPTT) clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity (FVIII:C). Thromb Haemost 2002;87:436-441.
22. Krudysz-Amblo J, Parhami-Seren B, Butenas S, Brummel-Ziedins KE, Gomperts ED, Rivard GE, Mann KG. Quantitation of antifactor VIII antibodies in human plasma. Blood 2009;113:2587-2594.
23. Le Gal G, Carrier M, Tierney S, Majeed H, Rodger M, Wells PS. Prediction of the warfarin maintence dose after completion of the 10mg nomogram: do we really need genotyping? J Thromb Haemost 2010;8:90-94.